Business
Biomea Fusion is a clinical-stage diabetes and obesity medicines company focused on oral small molecule drugs for diabetes, obesity, and other metabolic diseases.
Biomea is a clinical-stage diabetes and obesity drug developer with no revenue, a smaller FY2025 loss, and continued cash burn.
The read at a glance✓ Audited against SEC data
- Business mix — Oral metabolic drugsNote
- Revenue — No revenueWatch
- Loss — Net loss narrowed 55.4%OK
- FCF — -$70.4MWatch
- Equity — $29.6M, -42.7%Watch
- Insiders — $196.7K purchases / 0 salesOK
- Accounting — Forensic screens unavailableNote
Leadership changes
From Biomea Fusion, Inc.'s own filings, the day they're filed.
- Julianne Averill · Director · appointmenteff. 2025-07-22
- Bihua Chen · Director · departureeff. 2025-07-22
- Franco Valle · Chief Financial Officer · departureeff. 2025-03-07
Latest filings
- 8-K · Company announcement2026-08-05
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-06-11
- 10-Q · Quarterly report2026-05-11
- 8-K · Company announcement2026-05-11
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Biomea Fusion, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.